Matthew D Blunt

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 23

Top Topics

Inflammatory Response

Natural Killer Cells

Top Venues

Science advances

Immunotherapy advances

This page only lists publications with an associated author ORCID identifier.

Publications

Lara V Graham, Salim I Khakoo, Matthew D Blunt
NK Cells in the Lymph Nodes and Their Role in Anti-Tumour Immunity. Biomedicines 12 (8) (2024)
Matthew D Blunt, Hayden Fisher, Ralf Bernd Schittenhelm, Berenice Mbiribindi, Rebecca Fulton, Sajida Khan, Laura Espana-Serrano, Lara V Graham, Leidy Bastidas-Legarda, Daniel Burns, Sophie M S Khakoo, Salah Mansour, Jonathan W Essex, Rochelle Ayala, Jayajit Das, Anthony Wayne Purcell, Salim I Khakoo
The nuclear export protein XPO1 provides a peptide ligand for natural killer cells. Science advances 10 (34) (2024)
Lara V Graham, Salim I Khakoo, Matthew D Blunt
NK Cells in the Lymph Nodes and Their Role in Anti-Tumour Immunity. Biomedicines 12 (8) (2024)
Matthew D Blunt, Hayden Fisher, Ralf Bernd Schittenhelm, Berenice Mbiribindi, Rebecca Fulton, Sajida Khan, Laura Espana-Serrano, Lara V Graham, Leidy Bastidas-Legarda, Daniel Burns, Sophie M S Khakoo, Salah Mansour, Jonathan W Essex, Rochelle Ayala, Jayajit Das, Anthony Wayne Purcell, Salim I Khakoo
The nuclear export protein XPO1 provides a peptide ligand for natural killer cells. Science advances 10 (34) (2024)
Matthew D Blunt
Targeting CD161 in B-cell malignancies. Blood 143 (12) (2024)
Matthew D Blunt
Targeting CD161 in B-cell malignancies. Blood 143 (12) (2024)
Matthew D Blunt, Hayden Fisher, Ralf Bernd Schittenhelm, Berenice Mbiribindi, Rebecca Fulton, Sajida Khan, Laura Espana-Serrano, Lara V Graham, Leidy Bastidas-Legarda, Daniel Burns, Sophie M S Khakoo, Salah Mansour, Jonathan W Essex, Rochelle Ayala, Jayajit Das, Anthony Wayne Purcell, Salim I Khakoo
The nuclear export protein XPO1 provides a peptide ligand for natural killer cells. Science advances 10 (34) (2024)
Matthew D Blunt, Hayden Fisher, Ralf Bernd Schittenhelm, Berenice Mbiribindi, Rebecca Fulton, Sajida Khan, Laura Espana-Serrano, Lara V Graham, Leidy Bastidas-Legarda, Daniel Burns, Sophie M S Khakoo, Salah Mansour, Jonathan W Essex, Rochelle Ayala, Jayajit Das, Anthony Wayne Purcell, Salim I Khakoo
The nuclear export protein XPO1 provides a peptide ligand for natural killer cells. Science advances 10 (34) (2024)
Matthew D Blunt, Salim I Khakoo
Harnessing natural killer cell effector function against cancer. Immunotherapy advances 4 (1) (2023)
Matthew D Blunt, Salim I Khakoo
Harnessing natural killer cell effector function against cancer. Immunotherapy advances 4 (1) (2023)
Dean J Bryant, Lindsay Smith, Karly Rai Rogers-Broadway, Laura Karydis, Jeongmin Woo, Matthew D Blunt, Francesco Forconi, Freda K Stevenson, Christopher Goodnow, Amanda J Russell, Peter Humburg, Graham Packham, Andrew J Steele, Jonathan C Strefford
Network analysis reveals a major role for 14q32 cluster miRNAs in determining transcriptional differences between IGHV-mutated and unmutated CLL. Leukemia (2023)
Jack G Fisher, Amber D P Doyle, Lara V Graham, Shreyanshi Sonar, Benjamin Sale, Isla Henderson, Luis Del Rio, Peter W M Johnson, Yosef Landesman, Mark S Cragg, Francesco Forconi, Christopher J Walker, Salim I Khakoo, Matthew D Blunt
XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression. Leukemia (2023)
Matthew D Blunt, Salim I Khakoo
Harnessing natural killer cell effector function against cancer. Immunotherapy advances 4 (1) (2023)
Matthew D Blunt, Salim I Khakoo
Harnessing natural killer cell effector function against cancer. Immunotherapy advances 4 (1) (2023)
Jack G Fisher, Amber D P Doyle, Lara V Graham, Salim I Khakoo, Matthew D Blunt
Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer. Vaccines 10 (12) (2022)
Jack G Fisher, Amber D P Doyle, Lara V Graham, Salim I Khakoo, Matthew D Blunt
Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer. Vaccines 10 (12) (2022)
Jack G Fisher, Amber D P Doyle, Lara V Graham, Salim I Khakoo, Matthew D Blunt
Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer. Vaccines 10 (12) (2022)
Jack G Fisher, Amber D P Doyle, Lara V Graham, Salim I Khakoo, Matthew D Blunt
Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer. Vaccines 10 (12) (2022)
Jack G Fisher, Amber D P Doyle, Lara V Graham, Salim I Khakoo, Matthew D Blunt
Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer. Vaccines 10 (12) (2022)
Jack G Fisher, Amber D P Doyle, Lara V Graham, Salim I Khakoo, Matthew D Blunt
Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer. Vaccines 10 (12) (2022)
Matthew D Blunt, Sócrates Herrera Valencia, Jack G Fisher, Lara V Graham, Amber D P Doyle, Rebecca Fulton, Matthew J Carter, Marta E Polak, Peter W M Johnson, Mark S Cragg, Francesco Forconi, Salim I Khakoo
KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity. Journal of immunology (Baltimore, Md. : 1950) 209 (2) (2022)
Matthew D Blunt, Pauline Rettman, Leidy Y Bastidas-Legarda, Rebecca Fulton, Valentina Capizzuto, Mohammed M Naiyer, James A Traherne, Salim I Khakoo
A novel antibody combination to identify KIR2DS2high natural killer cells in KIR2DL3/L2/S2 heterozygous donors. HLA 93 (1) (2020)
Matthew D Blunt, Salim I Khakoo
Activating killer cell immunoglobulin-like receptors: Detection, function and therapeutic use. International journal of immunogenetics 47 (1) (2019)